ES2705027T3 - Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados - Google Patents

Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados Download PDF

Info

Publication number
ES2705027T3
ES2705027T3 ES11818848T ES11818848T ES2705027T3 ES 2705027 T3 ES2705027 T3 ES 2705027T3 ES 11818848 T ES11818848 T ES 11818848T ES 11818848 T ES11818848 T ES 11818848T ES 2705027 T3 ES2705027 T3 ES 2705027T3
Authority
ES
Spain
Prior art keywords
compound
disease
mammal
administration
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11818848T
Other languages
English (en)
Spanish (es)
Inventor
Varghese John
Dale E Bredesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buck Institute For Age Res
Buck Institute for Research on Aging
Original Assignee
Buck Institute For Age Res
Buck Institute for Research on Aging
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Institute For Age Res, Buck Institute for Research on Aging filed Critical Buck Institute For Age Res
Application granted granted Critical
Publication of ES2705027T3 publication Critical patent/ES2705027T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES11818848T 2010-08-19 2011-08-19 Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados Active ES2705027T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40190710P 2010-08-19 2010-08-19
PCT/US2011/048472 WO2012024616A1 (en) 2010-08-19 2011-08-19 Methods of treating miild cognitive impairment (mci) and related discorders

Publications (1)

Publication Number Publication Date
ES2705027T3 true ES2705027T3 (es) 2019-03-21

Family

ID=45605447

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11818848T Active ES2705027T3 (es) 2010-08-19 2011-08-19 Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados

Country Status (10)

Country Link
US (1) US10449177B2 (OSRAM)
EP (1) EP2605655B1 (OSRAM)
JP (2) JP6250394B2 (OSRAM)
AU (1) AU2011291506B2 (OSRAM)
BR (1) BR112013003847A8 (OSRAM)
CA (1) CA2808630A1 (OSRAM)
DK (1) DK2605655T3 (OSRAM)
ES (1) ES2705027T3 (OSRAM)
MX (1) MX353096B (OSRAM)
WO (1) WO2012024616A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013003847A8 (pt) 2010-08-19 2017-12-26 Buck Institute For Age Res métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
WO2014025905A1 (en) 2012-08-07 2014-02-13 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
EP3653609B1 (en) 2013-02-12 2024-04-03 Buck Institute for Research on Aging Hydantoins that modulate bace-mediated app processing
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
KR102645633B1 (ko) 2014-03-21 2024-03-11 알제온, 인크. 신경학적 장애를 치료하는 방법
AU2016220049C1 (en) 2015-02-18 2021-02-25 Buck Institute For Research On Aging Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
JP2018516901A (ja) * 2015-05-18 2018-06-28 シナプテック・ディヴェロップメント・エルエルシーＳｙｎａｐｔｅｃ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｌｃ アミロイドβのガランタミンクリアランス
PL3347002T3 (pl) * 2015-09-10 2023-11-13 Alzheon, Inc. Leczenie choroby alzheimera w konkretnej populacji pacjentów
US10441573B2 (en) 2015-12-09 2019-10-15 Brandeis University DBH inhibitors for treating memory loss
US20180250249A1 (en) * 2016-02-02 2018-09-06 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular population
US20190134000A1 (en) 2016-05-12 2019-05-09 Buck Institute For Research On Aging Compounds to promote normal processing of app
EP3565846A4 (en) 2017-01-03 2020-01-22 Bioatla, LLC PROTEIN THERAPEUTICS FOR THE TREATMENT OF SENESCENT CELLS
IL312612A (en) 2018-07-11 2024-07-01 Rubedo Life Sciences Inc Senolytic compositions and uses thereof
CN110232679A (zh) * 2019-05-24 2019-09-13 潘丹 一种阿尔茨海默症遗传生物标志物确定方法及系统
EP4005566B1 (en) 2019-07-25 2024-10-30 Tokyo University of Science Foundation Disulfiram and related compounds for treating, preventing or improving anxiety disorders or symptoms, and depressive disorders or symptoms

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
CA2085127C (en) 1990-06-15 2002-12-10 Barbara Cordell Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
DE69233774D1 (de) 1991-01-21 2009-12-10 Elan Pharm Inc Prüfung und Modell für Alzheimers-Krankheit
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
CA2127450C (en) 1992-01-07 2007-04-17 Samuel Wadsworth Transgenic animal models for alzheimer's disease
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
ES2155099T3 (es) 1993-10-27 2001-05-01 Elan Pharm Inc Animales transgenicos que albergan alelos app que presentan una mutacion sueca.
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
WO1996040885A2 (en) 1995-06-07 1996-12-19 Athena Neurosciences, Inc. β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
CN1198936C (zh) 1998-09-24 2005-04-27 法玛西雅厄普约翰美国公司 阿尔茨海默氏疾病分泌酶
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
WO2000059863A1 (en) 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US20040092511A1 (en) 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20070059367A1 (en) 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US20020115727A1 (en) 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
CA2503381A1 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
FR2846559B1 (fr) 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
AU2005217320B2 (en) 2004-02-26 2011-07-21 Aska Pharmaceuticals Co., Ltd. Pyrimidine derivative
AU2005235162B2 (en) 2004-04-21 2010-11-18 Mear Holding B.V. System for measuring pulsatile vascular resistance
EP1741430B1 (en) 2004-04-30 2009-07-15 National University Corporation Chiba University Remedy for psychoneurotic diseases
US8193250B2 (en) * 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
CA2590802A1 (en) 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
DE602005019210D1 (de) 2004-12-23 2010-03-18 Xenoport Inc Von serinaminosäure abgeleitete prodrugs von propofol, zusammensetzungen, anwendungen und kristalline formen davon
EP1885708A2 (en) 2005-04-15 2008-02-13 Board of Trustees of Michigan State University Gpcr modulators
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
EP1993542A1 (en) 2006-03-01 2008-11-26 Galderma Research & Development, S.N.C. Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof
KR101450356B1 (ko) * 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
WO2008074896A1 (en) * 2006-12-21 2008-06-26 Prendergast Patrick T Compositions and methods for treatment of chronic neurological disorders
EP2933243B1 (en) 2007-05-03 2017-11-01 Jack L. Arbiser Honokiol analogs and their use in treating cancers
EP2219449A4 (en) 2007-11-16 2010-10-27 Univ Arizona State METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
CL2007003877A1 (es) 2007-12-28 2008-06-27 Univ De Concepcion Lab Androma Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina.
ES2527448T3 (es) 2008-04-28 2015-01-23 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
EP2310019A4 (en) 2008-05-29 2011-06-01 Albany Molecular Res Inc 5-HT3 RECEPTOR MODULATORS, MANUFACTURING METHOD AND ITS USE
JP5514827B2 (ja) 2008-09-25 2014-06-04 バイオランド リミテッド ４−ｏ−メチルホノキオールを含有するアミロイド関連疾患の治療又は予防用組成物
CN102307574A (zh) 2008-10-08 2012-01-04 鲍斯生命科学Pvt有限公司 缓释给药系统
US20100099701A1 (en) 2008-10-20 2010-04-22 Auspex Pharmaceuticals, Inc. Isoquinolinone modulators of 5-ht3 receptors
CN101444508B (zh) 2008-12-29 2010-10-27 海南瑞基药物研究有限公司 一种注射用托烷司琼制剂及其制备方法
EP2432437A4 (en) 2009-05-21 2012-12-19 Bionex Pharmaceuticals Llc TWO- AND ONE-LAYER DOSAGE FORMS
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US9790109B2 (en) * 2010-04-30 2017-10-17 General Electric Company Method for sanitizing an electrodeionization device
BR112013003847A8 (pt) 2010-08-19 2017-12-26 Buck Institute For Age Res métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados
KR101368587B1 (ko) 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
WO2013123426A1 (en) 2012-02-18 2013-08-22 Buck Institute For Research On Aging Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions

Also Published As

Publication number Publication date
WO2012024616A1 (en) 2012-02-23
AU2011291506B2 (en) 2016-07-28
EP2605655B1 (en) 2018-10-24
US20120071468A1 (en) 2012-03-22
MX353096B (es) 2017-12-19
BR112013003847A2 (pt) 2016-05-31
JP6250394B2 (ja) 2017-12-20
DK2605655T3 (en) 2019-02-04
US10449177B2 (en) 2019-10-22
MX2013001917A (es) 2013-10-25
JP2013534256A (ja) 2013-09-02
EP2605655A1 (en) 2013-06-26
BR112013003847A8 (pt) 2017-12-26
EP2605655A4 (en) 2014-01-08
CA2808630A1 (en) 2012-02-23
AU2011291506A1 (en) 2013-03-14
JP2016193944A (ja) 2016-11-17

Similar Documents

Publication Publication Date Title
ES2705027T3 (es) Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
US10835546B2 (en) App specific BACE inhibitors (ASBIs) and uses thereof
Paris et al. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier
JP5303458B2 (ja) β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
ES2769578T3 (es) Hidantoínas que modulan el procesamiento de APP mediado por BACE
AU2008232614A1 (en) Method for the treatment of Fabry disease using pharmacological chaperones
US11369596B2 (en) Methods of treating a neurodegenerative disease in a mammal in need thereof
AU2017383127B2 (en) Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
US20090192199A1 (en) Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression
US9675627B2 (en) Dosing regimens for treating and/or preventing cerebral amyloidoses
US20130102538A1 (en) Method of treating alzheimer&#39;s disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity
WO2025095099A1 (ja) 前頭側頭葉変性症治療剤及び治療用組成物